These findings support the association between the CD44+CD24−/low phenotype of breast cancer tamoxifen-resistant cells and Sox2 expression and suggest that cells expressing high levels of Sox2 will be more resistant to tamoxifen. Here, SOX2 is linked to breast carcinoma.